drugset / Trial / NCT06471530
A Study to Investigate the Safety and Tolerability of TE-8105 in Overweight/Obese Participants Without Diabetes
Non-randomizedSequentialOpen-labelTreatment
Summary
This is a Phase 1/2a, first-in-human, prospective, open-label study to evaluate the safety, tolerability, PK, PD, and effect on body weight of TE-8105 in overweight/obese participants without diabetes. Study TE-8105-101 consists of 2 parts: Part A (single-ascending dose \[SAD\]) and Part B (multiple-ascending dose \[MAD\])
Timeline
- Start
- 2024-07-09
- Primary completion
- 2025-01-03
- Completion
- 2025-06-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | TE-8105 | Unknown | 0.5 mg | Subcutaneous |
| Subject | TE-8105 | Unknown | 0.75 mg | Subcutaneous |
| Subject | TE-8105 | Unknown | 1.5 mg | Subcutaneous |
| Subject | TE-8105 | Unknown | 2.5 mg | Subcutaneous |
| Subject | TE-8105 | Unknown | 3 mg | Subcutaneous |
| Subject | TE-8105 | Unknown | 5 mg | Subcutaneous |
| Subject | TE-8105 | Unknown | 6 mg | Subcutaneous |
Indications
No indication recorded.